|
|
Lentiviral vaccine vector |
|
Vaxvec ID |
22 |
|
Vaccine Vector Name |
Lentiviral vaccine vector |
|
Alternative Names |
lentivectors |
|
Vector VO ID |
VO_0000359
|
|
Function |
Lentivectors have been shown to result in extended transgene expression because of their ability to integrate genomes stably within chromatin sites that are transcriptionally active. They have been substituted in for γ-retrovirus vectors in human therapy (Liechtenstein et al., 2013). |
|
Advantage |
When comparing these vectors to other viral vectors, lentivectors contain important T cell adjuvant activities. They can productively transduce a a great variety of cell types, no matter their division status. Additionally, there exists less anti-vector immunity to lentiviral vectors than in the case of other viral vectors (Liechtenstein et al., 2013). |
|
Safety |
Lentivectors have been gradually enhanced to augment both their efficiency and biosafety (Liechtenstein et al., 2013). Because lentivectors appear to generate less genotoxicity, it is speculated that they may be safer than γ-retrovirus vectors. Specifically, the packaging plasmid in second generation lentivectors codes for gag-pol, rev and tat, but does not contain the remaining viral accessory genes (vif, vpr, vpu, nef). Safer than second generation lentivectors are third generation lentivectors, which are rev and tat-independent (Liechtenstein et al., 2013). |
|
Description |
Lentiviral vectors are virus-based gene vectors (Liechtenstein et al., 2013). |
| Related Vaccine(s) |
|
| References |
Coutant et al., 2012: Coutant F, Sanchez David RY, Félix T, Boulay A, Caleechurn L, Souque P, Thouvenot C, Bourgouin C, Beignon AS, Charneau P. A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria. PloS one. 2012; 7(11); e48644. [PubMed: 23133649].
Kim et al., 2013: Kim JH, Sohn HJ, Lee J, Yang HJ, Chwae YJ, Kim K, Park S, Shin HJ. Vaccination with lentiviral vector expressing the nfa1 gene confers a protective immune response to mice infected with Naegleria fowleri. Clinical and vaccine immunology : CVI. 2013; 20(7); 1055-1060. [PubMed: 23677321].
Liechtenstein et al., 2013: Liechtenstein T, Perez-Janices N, Escors D. Lentiviral vectors for cancer immunotherapy and clinical applications. Cancers. 2013; 5(3); 815-837. [PubMed: 24078865].
Lin et al., 2014: Lin L, Wei J, Chen Y, Huang A, Li KK, Zhang W. Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene. Journal of cancer research and clinical oncology. 2014; 140(2); 281-289. [PubMed: 24322180].
Xu et al., 2014: Xu Y, Yang E, Wang J, Li R, Li G, Liu G, Song N, Huang Q, Kong C, Wang H. Prime-boost BCG vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against M. tuberculosis in mice. Immunology. 2014; ; . [PubMed: 24773322].
|
|
